Search results for "target"

showing 10 items of 1196 documents

A Library-Based Screening Strategy for the Identification of DARPins as Ligands for Receptor-Targeted AAV and Lentiviral Vectors

2021

Delivering genes selectively to the therapeutically relevant cell type is among the prime goals of vector development. Here, we present a high-throughput selection and screening process that identifies designed ankyrin repeat proteins (DARPins) optimally suited for receptor-targeted gene delivery using adeno-associated viral (AAV) and lentiviral (LV) vectors. In particular, the process includes expression, purification, and in situ biotinylation of the extracellular domains of target receptors as Fc fusion proteins in mammalian cells and the selection of high-affinity binders by ribosome display from DARPin libraries each covering more than 1012 variants. This way, DARPins specific for the …

0301 basic medicinelcsh:QH426-470610 Medicine & healthComputational biologyQH426-470BiologyGene deliveryArticleViral vector03 medical and health sciences0302 clinical medicine1311 GeneticsLV10019 Department of Biochemistry1312 Molecular BiologyGeneticsVector (molecular biology)lcsh:QH573-671Molecular Biology030304 developmental biology0303 health sciencesQH573-671lcsh:Cytology10179 Institute of Medical Microbiologyribosome displayCorrectionAAVFusion proteinlcsh:GeneticsCD105NKp46DARPin030104 developmental biologyGluA4DARPin1313 Molecular Medicine030220 oncology & carcinogenesisBiotinylationRibosome displayreceptor-targeted viral vectors570 Life sciences; biologyMolecular MedicineAnkyrin repeatCytologyMolecular Therapy - Methods & Clinical Development
researchProduct

The Role of Next-Generation Sequencing in the Diagnosis of Lysosomal Storage Disorders

2016

Next-generation sequencing (NGS) panels are used widely in clinical diagnostics to identify genetic causes of various monogenic disease groups including neurometabolic disorders and, more recently, lysosomal storage disorders (LSDs). Many new challenges have been introduced through these new technologies, both at the laboratory level and at the bioinformatics level, with consequences including new requirements for interpretation of results, and for genetic counseling. We review some recent examples of the application of NGS technologies, with purely diagnostic and with both diagnostic and research aims, for establishing a rapid genetic diagnosis in LSDs. Given that NGS can be applied in a w…

0301 basic medicinelcsh:R5-920Emerging technologiesbusiness.industryEndocrinology Diabetes and MetabolismGenetic counselingLysosomal storage disordersComputational biology030105 genetics & heredityBioinformaticsTarget enrichmentMonogenic diseaseDNA sequencing03 medical and health sciences030104 developmental biologyPediatrics Perinatology and Child HealthMedicinelcsh:Medicine (General)businessGenetic diagnosisGenetics (clinical)Journal of Inborn Errors of Metabolism and Screening
researchProduct

Tailoring the Interface of Biomaterials to Design Effective Scaffolds

2018

Tissue engineering (TE) is a multidisciplinary science, which including principles from material science, biology and medicine aims to develop biological substitutes to restore damaged tissues and organs. A major challenge in TE is the choice of suitable biomaterial to fabricate a scaffold that mimics native extracellular matrix guiding resident stem cells to regenerate the functional tissue. Ideally, the biomaterial should be tailored in order that the final scaffold would be (i) biodegradable to be gradually replaced by regenerating new tissue, (ii) mechanically similar to the tissue to regenerate, (iii) porous to allow cell growth as nutrient, oxygen and waste transport and (iv) bioactiv…

0301 basic medicinelcsh:R5-920ScaffoldMaterials sciencelcsh:BiotechnologyBiomedical EngineeringTarget tissueBiomaterialNanotechnology02 engineering and technologyReview021001 nanoscience & nanotechnologyExtracellular matrixScaffold fabrication03 medical and health sciences030104 developmental biologyTissue engineeringlcsh:TP248.13-248.65tissue engineeringchitosanlcsh:Medicine (General)0210 nano-technologybiomaterialsJournal of Functional Biomaterials
researchProduct

IL-17 for therapy.

2017

The cytokine IL-17 is now a target for an array of therapeutic monoclonal antibodies supposed to treat a variety of inflammatory diseases. The forerunner Secukinumab, an IL-17A neutralizing antibody, is meanwhile approved as first-line treatments for moderate-to-severe plaque psoriasis, and as second-line treatment for psoriatic arthritis and ankylosing spondylitis. Ixekizumab and Brodalumab, both also targeting the IL-17 pathway, were also recently approved by the FDA for plaque psoriasis. Using mice overexpressing IL-17A in a tissue of choice, we showed that the ectopic expression of this cytokine in keratinocytes resulted in a spontaneous and very strong form of psoriasis-like dermatitis…

0301 basic medicinemedicine.drug_classBrodalumabDermatitisMice TransgenicDermatologyMonoclonal antibodymedicine.disease_causeAntibodies Monoclonal HumanizedBiochemistryAutoimmunity03 medical and health sciencesPsoriatic arthritisMice0302 clinical medicinePsoriasisMedicineAnimalsHumansPsoriasisSpondylitis AnkylosingMolecular Targeted TherapyMolecular BiologySkinbusiness.industryInterleukin-17Antibodies Monoclonalmedicine.diseaseIxekizumabDisease Models Animal030104 developmental biologyImmunologySecukinumabInterleukin 17business030215 immunologySignal TransductionJournal of dermatological science
researchProduct

E-beam crosslinked nanogels conjugated with monoclonal antibodies in targeting strategies

2017

Abstract Poly(N-vinyl pyrrolidone)-based-nanogels (NGs), produced by e-beam irradiation, are conjugated with monoclonal antibodies (mAb) for active targeting purposes. The uptake of immuno-functionalized nanogels is tested in an endothelial cell line, ECV304, using confocal and epifluorescence microscopy. Intracellular localization studies reveal a faster uptake of the immuno-nanogel conjugate with respect to the ‘bare’ nanogel. The specific internalization pathway of these immuno-nanogels is clarified by selective endocytosis inhibition experiments, flow cytometry and confocal microscopy. Active targeting ability is also verified by conjugating a monoclonal antibody which recognizes the αv…

0301 basic medicinemedicine.drug_classConfocalmedia_common.quotation_subjecthigh-energy irradiationClinical BiochemistryNG[object Object]02 engineering and technologyMonoclonal antibodyBiochemistryCell LineFlow cytometrylaw.invention03 medical and health sciencesConfocal microscopylawFluorescence microscopemedicineHumansInternalizationMolecular Biologymedia_commonradiation-engineeredDrug Carriersmedicine.diagnostic_testChemistrywound healing assay.antiβ3 integrin antibodyAntibodies MonoclonalPovidoneactive-targetingBiological Transport021001 nanoscience & nanotechnologyMolecular biologyNanostructures030104 developmental biologyTargeted drug deliverynanogelpoly(N-vinyl pyrrolidone)Biophysics0210 nano-technologyGelswound healing assayNanogelBiological Chemistry
researchProduct

A novel rationale for targeting FXI: Insights from the hemostatic microRNA targetome for emerging anticoagulant strategies

2021

Therapeutic targeting of blood coagulation is a challenging task as it interferes with the delicate balance of pro- and anticoagulant activities. Anticoagulants are employed in millions of thrombophilic patients worldwide each year. The treatment and prevention of venous thromboembolism has changed drastically. Traditional vitamin K antagonists are being replaced by direct oral anticoagulants (DOACs), which selectively target coagulation factors Xa or IIa. However for a growing population with comorbidities satisfying therapeutic options are still lacking and the quest for novel therapeutics continues. Recently, targeting factors XI or XII have emerged as new therapeutic strategies. As thes…

0301 basic medicinemedicine.drug_classPopulationVitamin kBioinformaticsTherapeutic targeting03 medical and health sciences0302 clinical medicinemicroRNAHumansMedicinePharmacology (medical)educationFactor XIPharmacologyHemostasiseducation.field_of_studybusiness.industryAnticoagulantAnticoagulantsThrombosisMicroRNAs030104 developmental biologyCoagulation030220 oncology & carcinogenesisHemostasisbusinessVenous thromboembolismPharmacology & Therapeutics
researchProduct

Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment.

2020

The deregulation of a wide variety of protein kinases is associated with cancer cell initiation and tumor progression. Owing to their indispensable function in signaling pathways driving malignant cell features, protein kinases constitute major therapeutic targets in cancer. Over the past two decades, intense efforts in drug development have been dedicated to this field. The development of protein kinase inhibitors (PKIs) have been a real breakthrough in targeted cancer therapy. Despite obvious successes across patients with different types of cancer, the development of PKI resistance still prevails. Combination therapies are part of a comprehensive approach to address the problem of drug r…

0301 basic medicinemedicine.drug_class[SDV]Life Sciences [q-bio]Nitric OxideBiochemistry03 medical and health sciences0302 clinical medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNitric Oxide DonorsMolecular Targeted TherapyProtein kinase AProtein Kinase InhibitorsPharmacologybusiness.industryKinaseCancerProtein kinase inhibitormedicine.disease3. Good health030104 developmental biologyDrug developmentTumor progressionDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer cellCancer researchSignal transductionbusinessProtein KinasesSignal TransductionBiochemical pharmacology
researchProduct

Interstitial lung disease in systemic sclerosis: current and future treatment.

2017

Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SSc–ILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis,…

0301 basic medicinemedicine.medical_specialtyPathologyFibrosiImmunologyInterstitial lung diseaseSclerodermaPulmonary function testingSclerodermaPathogenesis03 medical and health sciencesSystemic sclerosi0302 clinical medicineRheumatologyFibrosisPredictive Value of TestsRisk FactorsInternal medicineCase fatality ratemedicineAnimalsHumansImmunology and AllergyMolecular Targeted Therapyskin and connective tissue diseasesLungCause of death030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryInterstitial lung diseaseHematopoietic Stem Cell Transplantationrespiratory systemmedicine.diseaseRheumatologyRespiratory Function Testsrespiratory tract diseasesTreatmentSettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisTreatment OutcomebusinessLung Diseases InterstitialTomography X-Ray ComputedImmunosuppressive AgentsLung Transplantation
researchProduct

Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

2017

Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.

0301 basic medicinemedicine.medical_specialtyPathologyReceptor Platelet-Derived Growth Factor alphamedicine.medical_treatmentPDGFR-αAntineoplastic AgentsTargeted therapy03 medical and health sciences0302 clinical medicineGrowth factor receptorDoxorubicin; Olaratumab; PDGFR-α; Soft tissue sarcomas; Hematology; Oncology; Geriatrics and GerontologyInternal medicinemedicineHumansDoxorubicinOlaratumabSoft tissue sarcomaHematologybiologybusiness.industryAntibodies MonoclonalCancerSoft tissueSarcomaHematologySoft tissue sarcomasmedicine.disease030104 developmental biologyOncologyDoxorubicin030220 oncology & carcinogenesisbiology.proteinGeriatrics and GerontologybusinessPlatelet-derived growth factor receptormedicine.drugOlaratumab
researchProduct

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

2021

We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan&ndash

0301 basic medicinemedicine.medical_specialtyPrognostic factorobesityrenal cell carcinomaMultivariate analysisCabozantinibPrognosiClinical Biochemistrybody mass indexurologic and male genital diseasesGastroenterologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRenal cell carcinomacabozantinibInternal medicinemedicineOverall survivalIn patientneoplasmsPathologicallcsh:R5-920real-world databusiness.industrybody mass index; cabozantinib; obesity; prognosis; real-world data; renal cell carcinoma; targeted therapymedicine.diseasetargeted therapyfemale genital diseases and pregnancy complications030104 developmental biologychemistry030220 oncology & carcinogenesisprognosislcsh:Medicine (General)businessBody mass indexDiagnostics
researchProduct